Reuters
30 Sept 2026, 19:41 UTC · 1h ago
Verdict
Headline leans bearish. We score LQDA −1.00 across two claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
2 claims · scored −1 bearish … +1 bullish · 2 new · 0 priced in
A federal judge ruled that Liquidia's lung drug infringes a key patent held by United Therapeutics.
Newshares plunged on Wednesday
So whatThis legal defeat likely blocks immediate commercialization, severely impacting projected FY2026 and FY2027 revenue estimates.
More negative than 99% of claims this week
Liquidia shares fell nearly 50% on Wednesday following the court ruling.
Continue reading
5 related stories
More negative than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Newshares plunged on Wednesday
So whatThe massive valuation haircut reflects a pivot from growth expectations to a high-risk legal battle.
More negative than 84% of claims this week
Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
3h ago
−57.2%
Price agrees with the score
$30.26 vs $70.69 close before publication (Sep 29) · not market-adjusted
LQDA chart →
